Research seeks to prevent vision loss in infants with congenital glaucoma

Without treatment, congenital glaucoma can lead to vision loss, often before a baby ever takes his first steps.

Unraveling how this eye disease occurs is the goal of Colleen McDowell, PhD, Research Assistant Professor of Cell Biology and Immunology. A $60,000 grant from the Knights Templar Eye Foundation is funding her research on this condition that affects one in every 10,000 infants.

Unlike most types of glaucoma that develop slowly and occur late in life, congenital glaucoma is present at birth, develops quickly and is much more severe, Dr. McDowell said.

Normally fluid leaves a healthy eye through a tiny drain. The eye then makes more fluid to replace what is lost. But this balance is thrown off in an eye with glaucoma because the fluid does not drain properly.

“With congenital glaucoma, pressure in the eye gets really high, really fast,” Dr. McDowell said. “In small children this ends up killing cells in the back of the eyes that are responsible for vision.”

Her research will focus on pinpointing the cells that are dying first.

“If I can identity those that are dying the fastest, then it’s possible to target and save those cells first,” she said. “That can hopefully lead to therapies that prevent the death of the cells that are responsible for vision loss.”

The symptoms, which might not be apparent at birth, include light sensitivity and excessive tearing caused by malfunctions in the drainage system. Often the child’s eyes are unusually large because of high pressure building up, Dr. McDowell said.

If the disease is diagnosed early, structural damage can be treated with surgery and most children do well. But once vision is lost, it cannot be restored.

Dr. McDowell hopes that her research will lead to therapies that help prevent vision loss in children with the disease.

The Knights Templar Eye Foundation’s pediatric ophthalmology grants support researchers at the beginning of their careers who are committed to the prevention and cure of potentially blinding eye diseases in infants and children.

To date, it has directed more than $23 million to such research efforts.

Recent News

Abe Clark
  • Research
|Mar 28, 2024

Dr. Abe Clark honored with international research award

Abbot “Abe” Clark, PhD, FARVO, FAAO, regents professor of pharmacology and neuroscience in the School of Biomedical Sciences at The University of North Texas Health Science Center at Fort Worth, has received the International Society for Eye Research 2024 Ernst H. Bárány Prize.   The awar...
Processed With Lensa With Pt12 Filter
  • Research
|Mar 28, 2024

Dr. Steven Romero receives American Physiological Society award for excellence in research

Dr. Steven Romero, associate professor of Physiology and Anatomy at the School of Biomedical Sciences at The University of North Texas Health Science Center at Fort Worth, was named the 2024 Henry Pickering Bowditch Award Lecturer by the American Physiological Society. The lectureship is awarded to ...
Screenshot 2024 03 28 At 8.50.12 am
  • Our People
|Mar 28, 2024

Physical therapy student lands prestigious role in national organization

When Jonathan Hansen was an undergraduate intern at Texas Health Arlington Memorial Hospital, he encountered a man who had just suffered a stroke. The patient’s right side was completely paralyzed. Hansen, now a first-year student in The University of North Texas Health Science Center at Fort Wort...
Jackie In Dc
  • Our People
|Mar 27, 2024

Personalized Health and Well-Being student repays generosity through advocacy

In 2019, The University of North Texas Health Science Center at Fort Worth student Jacqueline Green said she felt hopeless. She became pregnant while experiencing hard financial times, and she didn’t have insurance. Compounding her stress was terrible grief. Her mother-in-law suddenly passed away,...